Literature DB >> 12782771

Management of asthma in adults: current therapy and future directions.

R H Green1, C E Brightling, I D Pavord, A J Wardlaw.   

Abstract

Asthma is increasing in prevalence worldwide and results in significant use of healthcare resources. Although most patients with asthma can be adequately treated with inhaled corticosteroids, an important number of patients require additional therapy and an increasing number of options are available. A further minority of patients develop severe persistent asthma which remains difficult to manage despite current pharmacological therapies. This review discusses the various treatment options currently available for each stage of asthma severity, highlights some of the limitations of current management, and outlines directions which may improve the management of asthma in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782771      PMCID: PMC1742702          DOI: 10.1136/pmj.79.931.259

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  103 in total

1.  Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.

Authors:  A P Sampson; S Siddiqui; D Buchanan; P H Howarth; S T Holgate; J W Holloway; I Sayers
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice.

Authors:  S Lim; A Jatakanon; D Gordon; C Macdonald; K F Chung; P J Barnes
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

3.  Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial.

Authors:  A Custovic; B M Simpson; A Simpson; P Kissen; A Woodcock
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

Review 4.  House dust mite control measures for asthma.

Authors:  P C Gøtzsche; H K Johansen; C Hammarquist; M L Burr
Journal:  Cochrane Database Syst Rev       Date:  2001

5.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Authors:  M Solèr; J Matz; R Townley; R Buhl; J O'Brien; H Fox; J Thirlwell; N Gupta; G Della Cioppa
Journal:  Eur Respir J       Date:  2001-08       Impact factor: 16.671

6.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Authors:  W Busse; J Corren; B Q Lanier; M McAlary; A Fowler-Taylor; G D Cioppa; A van As; N Gupta
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

Review 7.  Cross-talk between pro-inflammatory transcription factors and glucocorticoids.

Authors:  I M Adcock; G Caramori
Journal:  Immunol Cell Biol       Date:  2001-08       Impact factor: 5.126

8.  Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.

Authors:  J E Fish; E Israel; J J Murray; A Emmett; R Boone; S W Yancey; K A Rickard
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

9.  Qualitative study of views of health professionals and patients on guided self management plans for asthma.

Authors:  A Jones; R Pill; S Adams
Journal:  BMJ       Date:  2000-12-16

10.  Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.

Authors:  H S Nelson; W W Busse; E Kerwin; N Church; A Emmett; K Rickard; K Knobil
Journal:  J Allergy Clin Immunol       Date:  2000-12       Impact factor: 10.793

View more
  11 in total

1.  Similarities and differences between asthma health care professional and patient views regarding medication adherence.

Authors:  Sandra Peláez; Simon L Bacon; Mark W Aulls; Guillaume Lacoste; Kim L Lavoie
Journal:  Can Respir J       Date:  2014-04-07       Impact factor: 2.409

2.  Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation.

Authors:  Sébastien Talbot; Raja-Elie E Abdulnour; Patrick R Burkett; Seungkyu Lee; Shane J F Cronin; Maud A Pascal; Cedric Laedermann; Simmie L Foster; Johnathan V Tran; Nicole Lai; Isaac M Chiu; Nader Ghasemlou; Matthew DiBiase; David Roberson; Christian Von Hehn; Busranour Agac; Oliver Haworth; Hiroyuki Seki; Josef M Penninger; Vijay K Kuchroo; Bruce P Bean; Bruce D Levy; Clifford J Woolf
Journal:  Neuron       Date:  2015-06-25       Impact factor: 17.173

3.  Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics.

Authors:  A Sutcliffe; D Kaur; S Page; L Woodman; C L Armour; M Baraket; P Bradding; J M Hughes; C E Brightling
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

4.  Strategies to conserve salbutamol pressurized metered-dose inhaler stock levels amid COVID-19 drug shortage.

Authors:  Ali Elbeddini; Yasamin Tayefehchamani; Lucy Yang
Journal:  Drugs Ther Perspect       Date:  2020-07-25

5.  The Saudi Initiative for Asthma.

Authors:  Mohamed S Al-Moamary; Mohamed S Al-Hajjaj; Majdy M Idrees; Mohamed O Zeitouni; Mohammed O Alanezi; Hamdan H Al-Jahdali; Maha Al Dabbagh
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

Review 6.  Management of paediatric asthma.

Authors:  J Grigg
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

7.  Patient-centered care and its effect on outcomes in the treatment of asthma.

Authors:  Nashmia Qamar; Andrea A Pappalardo; Vineet M Arora; Valerie G Press
Journal:  Patient Relat Outcome Meas       Date:  2011-03-06

8.  Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics.

Authors:  Eef D Telenga; Huib A M Kerstjens; Nick H T Ten Hacken; Dirkje S Postma; Maarten van den Berge
Journal:  BMC Pulm Med       Date:  2013-09-22       Impact factor: 3.317

9.  Inhaled corticosteroids improve lung function, airway hyper-responsiveness and airway inflammation but not symptom control in patients with mild intermittent asthma: A meta-analysis.

Authors:  Wei Du; Ling Zhou; Yingmeng Ni; Yuanyuan Yu; Fang Wu; Guochao Shi
Journal:  Exp Ther Med       Date:  2017-06-27       Impact factor: 2.447

Review 10.  Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung.

Authors:  Leonor de Braganca; G John Ferguson; Jose Luis Santos; Jeremy P Derrick
Journal:  J Immunotoxicol       Date:  2021-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.